New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies
Author: Anonim
Publsiher: Academic Press
Total Pages: 250
Release: 2020-11-01
ISBN 10: 0128167378
ISBN 13: 9780128167373
Language: EN, FR, DE, ES & NL

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies Book Review:

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Yonsei Medical Journal

Yonsei Medical Journal
Author: Anonim
Publsiher: Unknown
Total Pages: 329
Release: 2007
ISBN 10:
ISBN 13: MINN:31951P01070862B
Language: EN, FR, DE, ES & NL

Yonsei Medical Journal Book Review:

Journal of the National Cancer Institute

Journal of the National Cancer Institute
Author: Anonim
Publsiher: Unknown
Total Pages: 329
Release: 2002-05
ISBN 10:
ISBN 13: UCBK:C077299690
Language: EN, FR, DE, ES & NL

Journal of the National Cancer Institute Book Review:

Immunogenic Cell Death in Cancer From Benchside Research to Bedside Reality

Immunogenic Cell Death in Cancer  From Benchside Research to Bedside Reality
Author: Abhishek D Garg,Patrizia Agostinis
Publsiher: Frontiers Media SA
Total Pages: 329
Release: 2016-04-29
ISBN 10: 2889198383
ISBN 13: 9782889198382
Language: EN, FR, DE, ES & NL

Immunogenic Cell Death in Cancer From Benchside Research to Bedside Reality Book Review:

Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.

Perry s The Chemotherapy Source Book

Perry s The Chemotherapy Source Book
Author: Michael C. Perry,Donald C. Doll,Carl E. Freter
Publsiher: Lippincott Williams & Wilkins
Total Pages: 848
Release: 2012-07-30
ISBN 10: 1469803437
ISBN 13: 9781469803432
Language: EN, FR, DE, ES & NL

Perry s The Chemotherapy Source Book Book Review:

Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

Non Myeloablative Allogeneic Transplantation

Non Myeloablative Allogeneic Transplantation
Author: Asad Bashey,Edward D. Ball
Publsiher: Springer Science & Business Media
Total Pages: 216
Release: 2002-02-28
ISBN 10: 9780792376460
ISBN 13: 0792376463
Language: EN, FR, DE, ES & NL

Non Myeloablative Allogeneic Transplantation Book Review:

Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.

Clinical Radiation Oncology E Book

Clinical Radiation Oncology E Book
Author: Leonard L. Gunderson,Joel E. Tepper
Publsiher: Elsevier Health Sciences
Total Pages: 1660
Release: 2011-09-16
ISBN 10: 1455726036
ISBN 13: 9781455726035
Language: EN, FR, DE, ES & NL

Clinical Radiation Oncology E Book Book Review:

With thorough updates throughout, Clinical Radiation Oncology provides the most comprehensive, authoritative, and up-to-date information available for treating patients with cancer. From a multidisciplinary perspective, this new edition, edited by Drs. Leonard L. Gunderson and Joel E. Tepper, examines the therapeutic management of specific disease sites based on both single-modality and combined-modality approaches - providing you with the well-rounded, cutting-edge guidance you need to offer the most effective treatments. A consistent chapter format, full-color design, and access to the full text at www.expertconsult.com make reference fast and easy. It is an ideal resource for mastering the latest, most effective techniques and modalities! Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities. Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons. Broaden your understanding of the basic biology of the disease processes. Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches. Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques. Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors –many of whom are new to this edition – affiliated with institutions across North America and internationally Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more! Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy. Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens. Understand and comply with the latest staging guidelines.

Lymphoma Pathology Diagnosis and Treatment

Lymphoma  Pathology  Diagnosis and Treatment
Author: Robert Marcus,John W. Sweetenham,Michael E. Williams
Publsiher: Cambridge University Press
Total Pages: 277
Release: 2007-06-21
ISBN 10: 9780521865449
ISBN 13: 0521865441
Language: EN, FR, DE, ES & NL

Lymphoma Pathology Diagnosis and Treatment Book Review:

Places the major advances which have occurred in the area of lymphoma into the context of daily clinical practice.

Pediatric Lymphomas

Pediatric Lymphomas
Author: Howard J. Weinstein,Melissa M. Hudson,Michael P. Link
Publsiher: Springer Science & Business Media
Total Pages: 292
Release: 2007-01-20
ISBN 10: 354068753X
ISBN 13: 9783540687535
Language: EN, FR, DE, ES & NL

Pediatric Lymphomas Book Review:

This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.

Dissertation Abstracts International

Dissertation Abstracts International
Author: Anonim
Publsiher: Unknown
Total Pages: 329
Release: 2008
ISBN 10:
ISBN 13: STANFORD:36105131549656
Language: EN, FR, DE, ES & NL

Dissertation Abstracts International Book Review:

Lymphoma

Lymphoma
Author: Anas Younes,Bertrand Coiffier
Publsiher: Springer Science & Business Media
Total Pages: 411
Release: 2013-05-17
ISBN 10: 1627034080
ISBN 13: 9781627034081
Language: EN, FR, DE, ES & NL

Lymphoma Book Review:

Recently, understanding the molecular pathogenesis of malignant lymphomas has led to improvement in the diagnostic precision and to the identification of a variety of molecular therapeutic targets. In addition, new drugs have been approved in the US and Europe, resulting in changes in the standard of care of several types of lymphoid malignancies. Comprehensive in scope and developed by a team of internationally renowned authors, Lymphoma: Diagnosis and Treatment provides a timely update on the most important advances in the biology, diagnosis, and therapy of lymphomas. As part of the Current Clinical Oncology series, Lymphoma: Diagnosis and Treatment will be of value to medical oncologists, hematologists, radiation oncologists, and all physicians involved in the care of patients with lymphoid malignancies.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Author: E. Campo,N. L. Harris,S. A. Pileri,E. S. Jaffe,H. Stein,J. Thiele
Publsiher: IARC Who Classification of Tum
Total Pages: 586
Release: 2017-09-18
ISBN 10: 9789283244943
ISBN 13: 928324494X
Language: EN, FR, DE, ES & NL

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Book Review:

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is a Revised Fourth Edition of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants further include new ICD-O codes, epidemiology, clinical features, macroscopy, prognosis, and predictive factors. This classification, prepared by 132 authors from 23 countries, contains about 1300 color images and tables and more than 4500 references.

The Journal of Immunology

The Journal of Immunology
Author: Anonim
Publsiher: Unknown
Total Pages: 329
Release: 2007
ISBN 10:
ISBN 13: UIUC:30112083160074
Language: EN, FR, DE, ES & NL

The Journal of Immunology Book Review:

Annual Meeting Proceedings

Annual Meeting Proceedings
Author: American Society of Clinical Oncology. Meeting
Publsiher: Unknown
Total Pages: 329
Release: 2007
ISBN 10:
ISBN 13: CHI:77004183
Language: EN, FR, DE, ES & NL

Annual Meeting Proceedings Book Review:

The Heart in Rheumatic Autoimmune and Inflammatory Diseases

The Heart in Rheumatic  Autoimmune and Inflammatory Diseases
Author: Udi Nussinovitch
Publsiher: Academic Press
Total Pages: 766
Release: 2017-02-10
ISBN 10: 0128032685
ISBN 13: 9780128032688
Language: EN, FR, DE, ES & NL

The Heart in Rheumatic Autoimmune and Inflammatory Diseases Book Review:

The prevalence of autoimmune diseases and rheumatic conditions is constantly increasing. Autoimmune diseases affect approximately 7-10% of the population of the United States, while more than 50,000,000 American adults suffer from some type of arthritis. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases examines the complex mechanisms relating to cardiac diseases from a pathophysiological and clinical point of view. Autoimmune rheumatic diseases can affect the coronary vessels, myocardium, pericardium, heart valves and the conduction system. The diagnosis of these unique cardiac complications necessitates medical awareness and a high index of suspicion. Increased risk of advanced atherosclerosis plays a pivotal role in the development of cardiac diseases in systemic, rheumatic and autoimmune illnesses. Yet, other complex immune medicated mechanisms may contribute to the pathogenesis. Patients' optimal care requires coordination between the primary caregiver, the rheumatologist, immunologist and cardiologist. Screening for cardiovascular risk factors, recognition of high-risk patients and identification of subclinical cardiac conditions are of great importance. Moreover, regulation of inflammation, as well as abnormal immune responses and the initiation of early treatments should be the focus of patient management. A continuous attempt to identify novel therapeutic targets and change the natural history of the underlying disease and its cardiac manifestations is in progress. The book aims at providing the readers with a state of the art collection of up to date information regarding clinically important topics based on experts' perspectives. This book was a result of an extended coordinated collaboration of one-hundred and fifty-four distinguished scientists from thirty-one countries around the globe. A review of common, as well as unusual (yet clinically significant) medical cardiac complications of prevalent rheumatic, autoimmune and inflammatory diseases. Focuses on aspects of pathophysiological processes, clinical presentations, screening tests, prognostic implications and novel therapeutic approaches. Presents an up-to-date “level of evidence and “strengths of recommendations for suggested therapies and reviews all randomized clinical trials, meta-analyses and other supporting published clinical findings.

Novel Therapeutics for Rare Lymphomas

Novel Therapeutics for Rare Lymphomas
Author: Christopher Dittus
Publsiher: Springer Nature
Total Pages: 253
Release: 2019-10-23
ISBN 10: 3030256103
ISBN 13: 9783030256104
Language: EN, FR, DE, ES & NL

Novel Therapeutics for Rare Lymphomas Book Review:

This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.

Intellectual Property Issues

Intellectual Property Issues
Author: Ulrich Storz,Wolfgang Flasche,Johanna Driehaus
Publsiher: Springer Science & Business Media
Total Pages: 108
Release: 2012-05-11
ISBN 10: 3642295266
ISBN 13: 9783642295263
Language: EN, FR, DE, ES & NL

Intellectual Property Issues Book Review:

SpringerBriefs in Biotech Patents present timely reports of intellectual properties (IP) issues and patent aspects in the field of biotechnology. This new volume in the series focuses on the particular IP issues of therapeutics, vaccines and molecular diagnostics. The first chapter concentrates on basics principles for protecting antibody compounds. Additional ways to create follow-up protection for antibody therapeutics are also discussed. The second chapter gives an overview of the patent landscape in molecular diagnostics, and discusses issues of patentability with respect to the different technologies and compounds used therein. The third chapter gives a broad overview of areas of law that are particularly relevant to the patenting of peptide vaccines and therapeutic peptides as products and in compositions. The scope of patentable subject matter is discussed, as it has been the focus of much wrangling and debate in the courts.

Hodgkin s and Non Hodgkin s Lymphoma

Hodgkin s and Non Hodgkin s Lymphoma
Author: John P. Leonard,Morton Coleman
Publsiher: Springer Science & Business Media
Total Pages: 476
Release: 2008-03-05
ISBN 10: 9780387293462
ISBN 13: 0387293469
Language: EN, FR, DE, ES & NL

Hodgkin s and Non Hodgkin s Lymphoma Book Review:

In recent years a dramatic increase in knowledge of the biology of the lymphomas has been accompanied by the emergence of new treatments offering improvements in efficacy and reduction in toxicity. In this volume an internationally recognized group of experts review relevant aspects of the biology, diagnosis and management, with particular emphasis on the emerging data available for this disease.

Macromolecular Anticancer Therapeutics

Macromolecular Anticancer Therapeutics
Author: L. Harivardhan Reddy,Patrick Couvreur
Publsiher: Springer Science & Business Media
Total Pages: 500
Release: 2010-03-20
ISBN 10: 9781441905079
ISBN 13: 1441905073
Language: EN, FR, DE, ES & NL

Macromolecular Anticancer Therapeutics Book Review:

In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context, Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as, enable the use of larger doses of these agents by limiting the toxicity, by enhanced permeability and retention into tumors, by tumor targeting using tumor-specific antibodies, by specific inhibition of oncogenes using anticancer oligonucleotides etc. Cancer treatment using this macromolecular therapeutics has considerably improved the survival benefit for patients. As a result, various macromolecular therapeutics are already commercialized or are under clinical development. Although we are far from a real magic bullet today, looking at the pace of research and current success in this field of macromolecular therapeutics, it appears that we are approaching a magic bullet for the efficient treatment of cancer. Thus, we believe that the subject of this book is very timely, and that the book will fill an unmet need in the market. This book is unique and assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy in one shell and conveys the importance of this interdisciplinary field to the broad audience. Thus, in a nutshell, this book details the basics of cancer, and various therapeutic strategies such as those based on macromolecular therapeutics hence can become an important reference for practitioners, oncologists, medical pharmacologists, medicinal chemists, biomedical scientists, experimental pharmacologists, pharmaceutical technologists, and particularly it can essentially become a handbook of macromolecular therapeutics for cancer therapy for graduates, post-graduates and Ph.D. students in these fields.

Autoimmune Bullous Diseases

Autoimmune Bullous Diseases
Author: Müzeyyen Gönül,Seray Çakmak
Publsiher: BoD – Books on Demand
Total Pages: 256
Release: 2018-05-09
ISBN 10: 1789230268
ISBN 13: 9781789230260
Language: EN, FR, DE, ES & NL

Autoimmune Bullous Diseases Book Review:

Autoimmune bullous diseases are a group of rare skin diseases characterized by intraepidermal and subepidermal bullae formations due to autoantibodies directed against the structural proteins of the epidermis or the dermal-epidermal junction. Early and correct diagnosis and adequate treatment of autoimmune bullous diseases are important as they cause morbidity and mortality in the affected patients. This book, which gives detailed information about autoimmune bullous diseases, has two sections and nine chapters with sixteen contributing authors. The first section describes the structure and tasks of desmosomes and basement membrane zone, which consist of the major antigens of skin integrity targeted by autoantibodies. The second section is about the epidemiology, etiopathogenesis, mucocutaneous, histopathologic and laboratory findings, and therapy of autoimmune bullous diseases.